Sign in
Taking people in United StatesNo phase

Studies genetic and environmental causes of Barrett's esophagus and esophageal cancer

Studies genetic and environmental factors in Barrett's esophagus and esophageal adenocarcinoma in adults.

Key facts

Who runs it
Case Western Reserve University
Where
Baltimore, Chapel Hill, Cleveland, New York, Philadelphia, Rochester, Seattle, and St Louis, United StatesSee the 10 sites
Trial code
Registry title
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
Status
Recruiting
People taking part
2,000 people, planned
Started
1 Oct 2005
Expected to end
31 Jul 2028
Type of study
Observational, 4 groups
Treatments tested
  • Balloon Capsule Device
  • Endoscopy
Record updated
10 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people with Barrett's esophagus or adenocarcinoma of the esophagus, and their family members, to study the genetic causes of these conditions.

Age
18 years or older. People under 18 can join with parental consent.
Sex
All sexes can join.
Disease stage
Barrett's esophagus confirmed by pathology and endoscopy reports, or adenocarcinoma of the esophagus. Family members of such patients can also join.

Main reasons for not taking part

  • Adults who cannot give informed consent cannot join.

The registry criteria, word for word

Show all 4 criteriaShow less

Other criteria

  • Eligible cases will be defined as those patients and their family members who meet the following criteria:
  • Barrett's esophagus confirmed by review of pathology and endoscopy report or adenocarcinoma of the esophagus or family members of person with Barrett's esophagus or adenocarcinoma of the esophagus
  • Male or female age 18 or older at time of enrollment or male or female less than 18 years of age at time of enrollment with parental consent
  • Ability to give informed consent, if patient is age 18 or older

Where in United States

  • Johns Hopkins HospitalBaltimore, United StatesContact: Marcia Canto, M.D.Taking people
  • University of North Carolina at Chapel HillChapel Hill, United StatesContact: Nicholas J Shaheen, M.D.Taking people
  • Cleveland ClinicCleveland, United StatesContact: Prashanthi Thota, MDTaking people
  • University Hospitals Of ClevelandCleveland, United StatesContact: Amitabh Chak, MDTaking people
  • Columbia University Medical CenterNew York, United StatesContact: Julian Abrams, MDTaking people
  • University of PennsylvaniaPhiladelphia, United StatesContact: Gary W Falk, MD, MSTaking people
  • Mayo ClinicRochester, United StatesContact: Ganapathy A Prasad, M.D.Taking people
  • Fred Hutchinson Cancer Research Center, UWMCSeattle, United StatesContact: William Grady, MDTaking people
  • VA Puget Sound Health Care SystemSeattle, United StatesContact: Andrew Kaz, MDTaking people
  • Washington University School of MedicineSt Louis, United StatesContact: Jean Wang, MDTaking people

About the trial

What the trial wants to find out

The overall objectives of this BETRNet Research Center (RC) are:

Read full original descriptionShow less

1. to conduct a rigorous, integrated spectrum of transdisciplinary human research in Barrett's esophagus (BE) and esophageal adenocarcinoma (ECA) 2. to increase the biological understanding of key observations made by our clinical researchers; 3. to translate knowledge derived from genetic, epigenetic, and transcriptome research to solving clinical dilemmas in detection, prognosis, prevention, and therapy of BE in order to prevent EAC and improve the outcomes of EAC; 4. to foster a transdisciplinary and translation research culture and to effectively expand and enhance scientific research focused on BE and EAC; 5. to evaluate research and transdisciplinary programs and to continuously improve research, productivity and enhance translational implementation. These objectives build and synergize on existing multi-institutional collaborative networks and the considerable clinical, basic science, and translational expertise available at our institutions, focusing on improving the outcomes of patients with BE and EAC. The overarching organization framework for this RC proposal is 1) to focus laboratory research on understanding the genetic susceptibility, genomic and epigenetic changes that influence the development of BE and EAC; and 2) to then translate laboratorydiscoveries into clinical applications for effective detection, molecular risk stratification, and prevention of progression from BE to EAC.

The 4 groups in the trial

  • Cases

    Patients with Barrett's esophagus undergoing surveillance or patients with esophageal adenocarcinoma and esophagogastric junctional adenocarcinoma undergoing EGD

    Treatment: Balloon Capsule Device and Endoscopy

  • EGD Screening

    Patients scheduled for clinically indicated EGD for GERD who meet ACG criteria for BE screening

    Treatment: Balloon Capsule Device and Endoscopy

  • Colon Screening

    Patients scheduled for screening colonoscopy who have not had EGD and meet clinically indicated criteria for BE screening

    Treatment: Balloon Capsule Device and Endoscopy

  • Controls

    Patients scheduled for EGD who do not meet criteria for screening

    Treatment: Balloon Capsule Device and Endoscopy

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Genetic and Environmental Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
Plain-language title
Studies genetic and environmental causes of Barrett's esophagus and esophageal cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Publications
Record updated
10 August 2026